A large real-world database to compare clinical outcomes of trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Mar 2022 New trial record
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium